Centenary of the 1918 influenza pandemic: preparing for the next one



7th - 10th September 2018

Beijing Conference Center
88 Laiguangying West Road, Chaoyang District, Beijing, China

This year marks the centenary of the first recorded influenza pandemic with devastating mortality globally in 1918. We had also experienced three subsequent influenza pandemics with the latest in 2009. Many lessons were learnt and influenza pandemic preparedness plans were revised and improved. However, many challenges remain and the 2018 World Influenza Conference was aimed at addressing the question on whether we are prepared for the next one.

The 2018 World Influenza Conference was hosted by the Chinese Association of Preventive Medicine (CPMA), China Center for Disease Control and Prevention (China CDC), Chinese Academy of Medical Sciences (CAMS), and the Asia-Pacific Alliance for the Control of Influenza (APACI). The conference was organized in collaboration with the European Scientific Working group on Influenza (ESWI), the National Adult and Influenza Immunization Summit (NAIIS) and the International Society for Influenza and other Respiratory Virus Diseases (isirv).


ZHANG Wenqing, Global Influenza Program, WHO. Pandemic Influenza Preparedness – a WHO Perspective

George Fu GAO, Director-General, China CDC. Overview of pandemic and pandemic preparedness in China

Rick BRIGHT, Director, Biomedical Advanced Research and Development Authority (USA). A multifaceted approach in the development of treatment and prevention of pandemic influenza: successes and challenges

WANG Chen, President, Chinese Academy of Medical Sciences (China). From SARS to influenza: the construction and improvement of China's clinical diagnosis and treatment system

Plenary Lectures 1 – global impact of influenza pandemics
Arnold MONTO (USA).  Impact and lessons learned from influenza pandemics in the last 100 years

Ab OSTERHAUS (Germany). Pandemic influenza viruses and avian viruses  

Ruben DONIS (USA). Pathogenic characteristics of pandemic influenza viruses

Mark JIT (UK). Economic impact of seasonal and pandemic influenza

Plenary Lectures 2 – pandemic preparedness plans and policy
ZHOU Weigong (WHO). Pandemic Influenza Preparedness - WHO’s efforts in countries support

Anne HUVOS (WHO). Access and benefit sharing: the objectives and progress of the WHO Pandemic Influenza Preparedness (PIP) framework

Massimo CIOTTI (ECDC). Influenza Pandemic Preparedness: Europe

Vernon LEE (Singapore). Influenza pandemic preparedness: perspectives from Singapore and Asia

Norio SUGAYA (Japan). Influenza antivirals usage in pandemic situation

Plenary Lectures 3 – elements of influenza pandemic readiness
SHU Yuelong (China). Improving the global surveillance network for novel influenza viruses with pandemic potentials

Hui-Ling YEN (China). Integration of animal influenza surveillance into influenza pandemic planning

Florian KRAMMER (USA). Global development of universal pandemic influenza vaccines

Marie MAZUR (USA). Use of adjuvant in influenza vaccines

Gary GROHMANN (Australia). Regulatory issues relating to rapid approval and distribution of pandemic influenza vaccines

CAO Bin (China). Progress of antiviral agents

JIANG Chengyu (China). Repurposing drugs to protect mice from H5N1 virus induced acute lung injury

Plenary Lectures 4 – elements of influenza pandemic response
ZHANG Wenqing (WHO). Vaccine response at the start of a pandemic – issues surrounding “switch” from seasonal to pandemic vaccine production

Woo Joo KIM (S. Korea). Extending lessons learned during the MERS outbreak to influenza pandemic response in South Korea

LI Qun (China). Review of the response to the 2009 H1N1 pandemic in China

Beverly TAYLOR (IFPMA). Global pandemic preparedness and response: manufacturers perspectives

David HUI (China). Extending clinical management of SARI during interpandemic time to address severe influenza in pandemics

Litjen TAN (USA). Advocacy and communication strategies to promote universal influenza vaccination in the USA: achievements and challenges

Plenary Lectures 5 – integrating seasonal influenza intervention strategies as part of pandemic planning
Joe BRESEE (USA). Seasonal influenza vaccine usage and pandemic preparedness planning

George KASSIANOS (UK). Strategies to increase seasonal influenza vaccine usage: UK experience

SHEN Kunling (China). Progress of clinical characters and treatments in children with influenza

Ben COWLING (China). Application and efficacy of interventions for influenza transmission in seasonal epidemics and pandemics

Break-out session 1: ensuring the adequacy of countries’ pandemic preparedness plans
Hitoshi OSHITANI (Japan). Pandemic preparedness planning in Asia: successes and gaps

Vincent PANG (Singapore). Strategies for evidence-based pandemic preparedness planning

David SMITH (Australia). Influenza Pandemic Planning: Australia and New Zealand

Hemant Chandra OJHA (Nepal). Influenza Pandemic Planning: Nepal

William AMPOFO (Ghana). Influenza Pandemic Preparedness: Africa

ZHOU Lei (China). Overview of H7N9 outbreak and response

HUANG Baoxu (China). Surveillance and control of avian influenza among poultry in China

Break-out session 2: pandemic influenza surveillance, laboratory diagnosis and early warning systems
WANG Dayan. Development of Influenza Surveillance Network in China

LI Chengjun (China). Evolution and control of H7N9 influenza viruses H7N9

SHU Yuelong (China). Lessons learned from H7N9 outbreak response for next pandemic preparedness and response

ZHANG Yanping (China). Surveillance of novel influenza virus in China

TIAN Huaiyu (China). Geneflow networks and spread of avian influenza virus

DU Xiangjun (China). Computational systems biology of influenza: a short story

Break-out session 3: effectiveness of public health  interventions for influenza in pandemics
ZHOU Weigong (WHO). Overview on guidance for non-pharmaceutical interventions

YANG Lin (China). Effectiveness of non-pharmaceutical interventions in controlling influenza in hospital settings

Ben COWLING (China). Evidence base and knowledge gaps on non-pharmaceutical interventions

WU Xiaoxing (China). Research on Influenza vaccine technology and the development of new influenza vaccine

YANG Yonghong (China). Protecting Chinese children from invasive pneumococcal diseases

Break-out session 4: implementation of seasonal and pandemic influenza vaccination
FENG Luzhao (China). Recommendation and policy of influenza vaccination in China

YU Hongjie (China). Cell culture-based recombinant influenza vaccines

Emanuele MONTOMOLI (Italy). Correlates of protection in influenza vaccine immunology

Parvaiz KOUL (India). Implementation of influenza vaccination in India: accomplishments and challenges

Burmaa ALEXANDER (Mongolia). Experience with influenza vaccine introduction in Mongolia

Anonh XEUATVONGSA (Lao). Lessons in sustainability of influenza vaccination programs – the Lao PDR experience

Pyanit THARMAPHORPILAS (Thailand). Thailand’s experience with expanding influenza vaccination

Yao Hangping (China). Novel strategies for prevention of influenza-universal influenza vaccine / prophylactic Immunomodulator

Break-out session 5: implementation of seasonal and pandemic antiviral treatment
Arnold MONTO (US). How should oseltamivir be used?

WENG Heng (China). Clinical evidence of NAIs on prevention and treatment of influenza

LU Hongzhou (China). Influenza standardized treatment

GUO Qiang (China). The therapeutic value of favipiravir on influenza and other viruses

David HUI (China). The role of adjuvant immunomodulatory agents for the treatment of severe influenza

CAO Bin (China). The clinical trial progress of baloxavir marboxil

JIA Zhenhua(China). Clinical value of traditional Chinese Medicine in the prevention and treatment of influenza

Break-out session 6: influenza virology and basic research to address pandemic readiness
Jennifer GORDAN & Alison AUGUSTINE (USA). NIAID’s Priorities to support broadly protective influenza vaccines

XU Jianqing (China). Protective immune responses during H7N9 infection

Florian KRAMMER (USA). Universal influenza vaccine development based on the conserved stalk domain of the influenza virus hemagglutinin

LIU Wenjun (China). Phosphyorylation Controls the Replication of influenza Virus

WANG Jianwei (China). Host factors involved in influenza virus infection: new targets for intervention

DENG Tao (China). Further characterizing the non-coding regions of influenza viruses

XU Ke (China). Histone demethylase LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation


CPMAlogo1 CDC logoAPACI 100

logo with subNAIISlogoisirv logo